Norwegian Centre for Mental

(1)

1 | N O R M E N T A n n u a l R e p o r t 2 0 1 5

NORMENT

Annual Report 2015

(2)

Norwegian Centre for Mental

Disorders Research (NORMENT)

3 Leader’s comments 4 Vision Statement 5 Scientific aims 6 Scientific currency

7 NORMENT Annual Retreat 8 Core Researchers

9 Translational Psychiatry 10 Clinical Psychosis Research 11 Neurocognition

12 Animal models 13 Structural MRI

14 Psychiatric Molecular Genetics 15 Brain Imaging

16 Convergent functional genomics 17 International Cooperation 18 New employees 2014 19 NORMENT Staff 21 Activities 2014 Visits Abroad Visits from Abroad

23 NORMENT leads new initiative 24 Selected presentations

26 Disputations

27 NORMENT in Media 28 Publications

34 Funding

Norwegian Centre for Mental Disorders Research (NORMENT) is a Norwegian Centre of

Excellence established by the Research Council of Norway in July 2013.

NORMENT is integrated with the K. G. Jebsen Centre for Psychosis Research, funded by the K.G. Jebsen Foundation. This provides a unique opportunity to perform comprehensive and long- term research, reaching across the country.

The Centre has a clear clinical profile, involving investigations of patients with state-of-the art clinical assessments and research technology, and translating findings to experimental studies for the identification of underlying mechanisms.

We have ambitious scientific goals, focusing on understanding the underlying mechanisms of severe mental disorders. This is a field with large unmet needs and lack of knowledge, which makes the work of our Centre of Excellence very important. We have focused on four main areas of activities to answer the following research questions:

 Why do antipsychotic medications have severe side effects?

 How can brain imaging help linking genes to clinical characteristics?

 Where is the ‘hidden heritability’ of severe mental disorders?

 How can we predict outcome in patients experiencing their first signs of disease?

(3)

Leader’s comments

I am pleased to present the 2015 report from our Centre of Excellence (CoE) NORMENT. It has been a very fruitful year with important achievements and discoveries. We have now established the organization and infrastructure, and are able to build on our vertical synergy approach to move the field forward.

An important aspect of CoE is to facilitate interactions and synergy between the different groups, and here we have succeeded with our Vertical Synergy Meetings. In these workshops the frontline status in a field is presented, and then we discuss ongoing and plan future projects in an interactive way, involving junior and senior Centre members. This has led to rewarding

scientific discussions, better project management and coordination, and identification of novel project opportunities and plans.

I am happy that we have continued publishing high impact papers in the most prestigious journals in 2015. We have participated in several important studies discovering new gene variants associated with phenotypes relevant for psychiatric disorders, such as brain structures as revealed by brain imaging. This has been based on both European and US grants.

The CoE researchers have contributed to new discoveries in all of our four main research areas. We have continued to develop new statistical tools essential for the next phase of studies, obtained new understanding about the connectivity in the brain, and specifically relating this to other levels of explanation, such as polygenic risk and symptoms and behaviour. We have also followed up these studies with experimental work to investigate underlying mechanisms.

In 2015 we were successful in obtaining external funding – both from The Research Council of Norway and the regional Health Authorities, as well as from international sources. Most of the budget is based on external grants, which makes it important to continuously look for new ideas and opportunities.

An important focus for our Centre is to recruit and engage young talented researchers. We organized the first Young Scientist Symposium, where the young people at the Centre met and learned to know each other and discussed ongoing projects and new plans. It is important for the success of the Centre that we get a functional young scientist team – so that we continue to generate new ideas and

generate energy and enthusiasm for research in severe mental illness.

In 2015 we also made important steps forward in integrating user groups in the centre. We have a close collaboration with users who have important input to project planning, but also to our

dissemination work. We will increase these efforts in 2016 and continue to improve the relationship with users.

This makes me very optimistic for the next year and I look forward to new discoveries in 2016.

Ole A. Andreassen, Centre leader

Ole A. Andreassen

(4)

Vision statement

NORMENT’s primary objective is to reveal underlying pathophysiological mechanisms in

schizophrenia and bipolar disorder and to develop tools for stratification and outcome prediction, using a vertical synergy approach. We have the following main aims:

• Define new targets to optimize the ratio of beneficial vs. adverse effects

• Use genetic and environmental factors to predict disease progress and outcome.

• Identify genetic variants or expression variation to reveal ‘missing heritability’

• Determine new brain imaging phenotypes linking genes and core clinical phenotypes.

We will take advantage of the homogeneity of the Norwegian population (genetic background, health care system, registries) as the basis for collecting large samples of affected and unaffected people.

These individuals will be characterized with the same clinical, cognitive, biochemical and imaging protocols to identify new mechanisms which will be studied functionally in animal and cell culture models.

Scientific aims

1. Define New Targets for Antipsychotic Medication

Antipsychotic medications are the cornerstone in the treatment of schizophrenia, and have in recent years also been used for bipolar disorder. The medications are not equally effective for all patients, and have a limited effect on the core symptoms for approximately 20 % of those treated.

Adverse effects are problematic and in some cases serious, such as cardiovascular risk factors (weight gain, abnormal fat levels in the blood, diabetes etc.). Research at NORMENT has a particular focus on the immune and lipid (fat) metabolism systems. We use animal and other experimental models to enhance our knowledge about the mechanisms of action of antipsychotic medication. We aim to optimize antipsychotic treatment by increasing the therapeutic effect of medication and reducing adverse effects.

2. Identify Genetic Factors for Psychiatric Disorders – Common and Rare Variants

Family and twin studies have shown that schizophrenia and bipolar disorder have high heritability.

Researchers at NORMENT have contributed to major international GWAS (“genome-wide association studies”). We have found evidence for new vulnerability genes for these disorders.

Preliminary results show that inherited changes in many genes (i.e. gene variants) are involved, but each variant contributes to a relatively modest degree. The identified gene variants explain only a small portion of susceptibility to psychotic disorders. Heritability is therefore still far from fully explained. In our research, we use combined approaches that include new genotyping methods to identify rare genetic variants. We also use new statistical methods for mapping multiple gene variants, each of which has a small effect on its own.

(5)

5 | N O R M E N T A n n u a l R e p o r t 2 0 1 5 3. Predict Course and Outcome –Including Mortality

Some patients with severe mental disorders recover completely while others develop chronic illness. Currently, we can mainly make general assumptions about the most likely prognosis for someone who develops a severe mental illness and are not able to predict the personal outcome for individual patients. One of the main goals for NORMENT is to investigate how we can improve our understanding of course and outcome. Ultimately, the goal is to make personalized predictions for patients coming to their first treatment. We are doing this by examining how genetic- and environmental risk factors influence the course of the disorder, by combining clinical- and cognitive assessments with brain imaging.

The main focus has been on investigating how specific environmental risk factors influence clinical-, cognitive- and morphological characteristics either individually, or in interaction with other environmental and genetic risk factors. At present, we are studying the effects of early traumatic events, cannabis use and migration- with additional studies of how the effects of trauma interact with the effects of cannabis use and of migration. We have also studied how trauma interacts with genetic factors – in this case variant in the BDNF gene – on cognition and on structural changes in hippocampal subfields.

This line of research is done in close collaboration with several of NORMENT’s groups and with international colleagues in Paris, France and Milan, Italy. To study the effects on course and outcome we also need well-described patient cohorts followed from their first treatment. Within the NORMENT Centre we have established a large first-treatment schizophrenia spectrum cohort and are working to establish a first-treatment bipolar spectrum cohort in collaboration with Norwegian colleagues in the NORSMI network. We have launched a 10-year) follow up of the schizophrenia cohort from the TOP study and have started a five-year follow up of patients at Innlandet Hospital in collaboration with the regional research network. The first part of the long- term follow-up will have a particular focus on functioning, cognition and negative symptoms.

4. Brain Imaging: Identify Brain MRI Phenotypes Linking Genes to Core Clinical Phenotypes

Advanced neuroimaging techniques including structural and functional MRI have revolutionized the understanding of the structural and functional makeup of the human brain. NORMENT

researchers have contributed to the identification of structural brain abnormalities in schizophrenia, including volumetric alterations in front temporal cortical areas and subcortical structures. Partly overlapping and partly diverging patterns have been found in bipolar disorder.

Structural and functional brain phenotypes are highly heritable, and current research at

NORMENT aims to identify the genetic underpinnings of individual differences in the structural and functional organization of the human brain, and to disentangle the genetic and phenotypic

associations with severe neuropsychiatric disorders.

(6)

60 % 32 %

8 %

Impact Factor Distribution - NORMENT Publications 2014

< 5 5 - 15

> 15

Scientific currency

Publication in international scientific journals NORMENT scientist authored or co-authored

133 papers in international peer-reviewed journals in 2015. Of these publications, 31 papers appeared in journals with an impact factor above 5. Seven of these appeared in journals with an impact factor above 15.

NORMENT has a focus on vertical synergy and will in each of our four main research areas aim to obtain different levels of understanding, bringing together transdisciplinary expertise and

methods. To achieve this goal, we have developed a meeting place, the monthly Vertical Synergy Meetings, where we at the practical level can facilitate interactions and discussions. First, there is a presentation of state of the art in a given topic, then overview of ongoing projects to facilitate

interaction and coordination, and then we end the workshop with discussion of new plans and projects.

This has in 2015 been implemented in a successful way to achieve synergy and initiate novel projects.

Dissemination of research result

NORMENT members gave 84 talks as invited speakers at international scientific meetings in 2015. In addition, 43 oral presentations and 46 posters were presented by NORMENT scientists. In addition, NORMENT staff gave 50 lectures, aimed at a targeted audience and the general public.

These include postgraduate lectures, research seminars, and training courses at universities and hospitals. Talks, posters, dissemination activities and media coverage are listed in the back of this report.

Prizes and awards:

 Aas, M. Scandinavian College of Neuropsychopharmacology (SCNP) Young Scientist Award

 Kaufmann, T. Pris for fremragende originalartikkel publisert 1. halvår 2015: Disintegration of Sensorimotor Brain Networks in Schizophrenia [doi:10.1093/schbul/sbv060]

 Quintana, D.: Society of Biological Psychiatry (SOBP) International Travel Fellowship

(7)

Annual Retreat 2015

NORMENT Annual Retreat 2015 took place at Grand Hotel Terminus in Bergen, September 15-17.

The program consisted of plenary lectures with updates, new findings and ongoing projects, synergy workshops with project planning, as well as poster sessions.

In addition, there were presentations by our Scientific Advisory Board, who also contributed with comments and feedback. A total of 85 people participated, in an enthusiastic and interactive atmosphere, and we had a successful annual NORMENT dinner.

Post doc Daniel Quintana presenting “The effect of intranasal oxytocin on social cognition and neural activity”

Vidar M. Steen, Marthe Løkken and Ingrid Melle leading the discussion: "How can we integrate and interact with patient groups in our research"

(8)

Core competency at NORMENT

NORMENT has organized the research into interdisciplinary research groups with complementary expertise. Each

research group is led by a senior researcher. NORMENT

has eight Core Researchers.

(9)

Translational Psychiatry

Group leader:

Ole A. Andreassen, Professor UiO, OUS Group members:

Ingrid Dieset (co-leader) Andrew Brown

Elin Reponen Thomas Bjella Saurabh Srinivasan Eva Zsuzsanna Hoseth Yunpeng Wang

Sigrun Hope Eivind Bakken Francesco Bettella Tuomo Mikael Marttunen Ragni Mørch

Wen Li

Olav Smeland Martin Tesli Nils Eiel Steen Terje Nærland Aree Witoelar Verena Zuber

Multimodal MRI Group Leader Lars T. Westlye Daniel Quintana Karolina Kauppi Tobias Kaufmann Nhat Trung Doan Christine Lycke Brandt Kristina Skåtun Ingeborg Bolstad

Achievements in 2015

 Actively involved in the ENIGMA consortium which discovered gene variants associated with subcortical brain structures

 Identified brain networks critical to brain function (and dysfunction) applying novel MRI analytical tools

 Developed further tools for statistical modelling of the genetic architecture of polygenic complex disorders, and discovered overlapping genes between brain disorders and cardiovascular disease.

 Determined immune factors related to severe mental illness, brain function and cardiovascular comorbidity.

Ambitions for 2016

Ambitions for 2016

 Finish the final phase of large Scandinavian genetic efforts (long range phasing) using our large Norwegian sample, and apply this approach to severe mental illness.

 Develop biostatistical tools for prediction, and apply them to mental illness phenotypes including brain and imaging phenotypes.

 Integrate more phenotypes and genetic markers in the computational neuroscience approach (“biophysical psychiatry”) and make plans for stem cell investigations.

 Increase the sample size for investigations of immune and cardiovascular comorbidity, using national networks.

(10)

Clinical Psychosis Research

Achievements in 2015

The focus of the Clinical research group (Melle CR node) is NORMENTs main aim number 4, the study on how gene x environment interactions influence the early- and long term course of schizophrenia and bipolar disorders. The main research achievements in 2015 are:

o Completed the one-year follow up part of the early bipolar study.

o Started the long-term (10 year) follow- up of first part of

“TOP cohort”.

o Started pilot phase of electronic data collection (“TSD App project”).

o Key papers on the role of environmental risk factors in schizophrenia and bipolar disorder.

Ambitions for 2016

 Broaden and expand the long-term follow-up study, also including register data.

 Revise clinical baseline protocol to improve characterization central to outcome prediction.

 Revise clinical protocol to improve valid measurements of central clinical phenomena.

 Complete pilot and first phase of “TSD App project”.

 Expand within-center collaboration concerning risk factor effects (methylation, stem cells).

Group leader:

Ingrid Melle,

Professor UiO, OUS.

Group members:

Trine Vik Lagerberg Carmen Simonsen Akiah Ottesen Berg Monica Aas

Sofie Aminoff Tone Hellvin

Camilla Bakkalia Büchman Christine Demmo

Erlend Gardsjord

Jannicke Fjæra Andersen Levi Kvitland

Mari Nerhus Marit Haram Tiril Østefjells Siv Hege Lyngstad Ida Bernadotte Huflåtten Seyran Khalili

(11)

Neurocognition

Group leader:

Kjetil Sundet, Professor UiO

Group members:

Torill Ueland Thomas Espeseth Anja Vaskinn Verónica Expósito Christine Demmo Beathe Haatveit June Lystad

Jens Marius Halvorsen Samira Aminihajibashi Maj Egeland

Magnus Engen Vilja Bidtnes Kristoffer Grimstad Tale Moldestad

Achievements in 2015

 Cognitive remediation and vocational rehabilitation projects, including JUMP study, finalized (PI: Torill Ueland).

 Social cognitive training project expanded with PhD student (PI:

Anja Vaskinn).

 Long term outcome project launched with PhD student focusing on neurocognitive predictors and trajectories at 10 year follow- up (PI: Torill Ueland).

 Genetics of attention and effort project expanded with second PhD student and postdoc fellow (PI: Thomas Espeseth).

 29 papers being published in 2015. Group also contributed with chapter to book on psychosis and society.

Ambitions for 2016

 Continue data collection of ongoing projects (long term outcome and social cognition training) and publish on baseline characteristics to secure PhD progress.

 Seek research grant to initiate study on ecological validity of social and emotional processing in psychosis, and to refine ongoing study of genetics of attention and effort.

 Submit two PhD theses from neurocognitive group (on executive functioning and on cognitive remediation and vocational rehabilitation).

 Re-establish group of research assistants for neurocognitive assessments.

 Recruit new group leader for neurocognitive group.

(12)

Animal models

Group leader:

Vidar M. Steen, Professor UiB

Group members:

Silje Skrede Kari M Ersland Tomasz Stokowy Raj Bose

Priyanthi B Gjerde Inger H Duus Christine Stansberg Rita Holdhus

Hans-Richard Brattbakk Marianne Navdal Jorunn S Bringsli

Achievements in 2015

 Explored and consolidated the study of antipsychotic depot drugs in rat, focusing on gender differences and experimental demyelination models.

 Developed a new software tool (RareVariantVis) for visualization and analysis of whole exome and whole genome data.

 Participated in international consortia, to define the polygenic background of human brain structures and cognitive functions.

Ambitions for 2016

 Examine the clinical, cognitive, psychopharmacological and biochemical relationships between therapeutic response and metabolic adverse effects of antipsychotic drugs in patients with psychosis.

 Explore the transcriptomic profiles in peripheral blood in patients with psychosis (schizophrenia and bipolar disorder) and health controls, using large number of samples from the TOP and Bergen Psychosis 2 project.

 Identify the biological effects in the brain and peripheral tissues of long-term exposure of antipsychotic depot drugs, using rats as a model.

(13)

Achievements in 2015

 Continued the search for biological and environmental correlates/effects to brain neuroanatomical changes. This year we present findings on

morphological brain correlates from use of prescription drugs (antipsychotics and Lithium) and tobacco.

 We demonstrate that both second- and first generation antipsychotics affect the subcortical brain in similar way but clozapine does not induce brain change.

 The hippocampus demonstrates field specific changes in severe psychosis.

 The first longitudinal neuroimaging study of first-episode psychosis shows stability of brain change over the first year after psychosis onset.

Structural MRI

Ambitions for 2016

 Use newly developed algorithms and software to find new imaging phenotypes (cortical gyrification, automated WMHI characterization, Free-water DTI and myelin mapping.

 Investigate pre- and perinatal risk factors and new biomarkers for effects on brain neuroanatomy and function in schizophrenia and bipolar disorder.

 Use national registry data for detailed evaluation of pharmacological effects on brain in adolescents and adult samples. What are the long-term effects?

 Develop and coordinate an ENIGMA for early onset adolescent psychosis, meta-analyses across international sites.

Group leader:

Ingrid Agartz, Professor UiO Group members:

Erik Jönsson

Unn Kristin H. Haukvik Ragnar Nesvåg Tiril Pedersen Gurholt Cecilie Bhandari Hartberg Andrea Raballo Elisabeth Lange Kjetil Nordbø Jørgensen

Lynn Mørch-Johnsen Kristine Engen Vera Lonning Runar Smelror Stener Nerland Linn Buenaventura Norbom

(14)

Ambitions for 2016

 Produce and further characterize induced pluripotent stem cells and induced neurons

 Intensify disease modelling using stem cell

 Extend translational projects

 Explore how cortical network dynamics are related to genetics of psychotic disorders

 Improve genetic prediction tools for disease course and outcome

 Further strengthening of international collaboration (eg.

EURICND, CNV ENIGMA, PGC BD,)

Achievements in 2015

 Several translational studies published and/or submitted

 Inclusion of samples for stem cells project and building up stem cells infrastructure

 Infrastructure / platform activities: biobanking, database, sample prep, QC

 3 new postdocs recruited

 Identifying the polygenic basis of the human brain and neurodevelopmental disorders

 New national /international collaborations established

Psychiatric Molecular Genetics

Group leader:

Srdjan Djurovic, Professor OUS, UiB.

Group members:

Lavinia Athanasiu Ida Elken Sønderby Sahar Hassani Lars Hansson Elin Inderhaug Matthieu Vandenberghe Agata Impellizzeri Christian M. Jørgensen Kristine Kjeldal

Attila Szabo Associates:

Timothy Hughes Olav B. Smeland Mari Tinholt Pietro Grassi Mumtaz H. Taqi

(15)

Brain Imaging, Cognition

Group leader:

Kenneth Hugdahl, Professor UiB Group members:

Lena Stabell Galyna Kovalchuk Lyn Marqueardt Alex Craven Geard Dwyer Liv Falkenberg Other personnel Renate Grüner Lars Ersland Erik Johnsen Rune Kroken Frank Larøi Else-Marie Løberg Kristiina Kompus Marco Hirnstein Josef Bless

Katarzyna Kazimierczak Justyna Beresniewicz

Achievements in 2015

 Found positive correlation between frequency and severity of auditory hallucinations and glutamate concentration in the speech perception areas in the temporal lobe (Hugdahl et al., Schiz Res, 2015, 161, 252-260)

 Discovered new cortical network, the extrinsic mode network, EMN, which is a non-specific general cognitive network (Hugdahl et al., Front Hum Neuroscience, http://dx.doi.org/10.3389/fnhum.2015.00430)

 Developed a new app-based method for sampling of symptom scores on-line, the app will be tested out in Bergen, Oslo and Turku, Finland

Ambitions for 2016

 Pursue the MR spectroscopy measurements, to include also GABA measurements in addition to glutamate, in order to contrast a major excitatory and inhibitory neurotransmitter and how the glutamate/GABA balance relates to the spontaneous onset and offset of auditory hallucinations.

 Mapping the major neurotransmitters behind auditory hallucinations is expected to be a major breakthrough if the relation exists.

 Initiate new studies on the relation between the cognitive EMN and the resting-state DMN networks interact in auditory hallucinations.

(16)

Convergent functional genomics and epigenetics

Achievements in 2015

 Finalized the pipeline to test for region based allelic heterogeneity association across traits. This required development and

implementation of methods for regions based association.

 Pilot project for the effect of cannabis of methylation of CpG islands in the blood of patients smoking cannabis.

 Show that regions differentially methylated in modern humans contra Neanderthal and denisovan, might have enrichment for association in schizophrenia.

 Participated in consortia for the identification of genetic variants implicated in cognition and brain imaging traits (ENIGMA;

CHARGE, COGENT).

Group leader:

Stéphanie le Hellard, Professor UiB

Group members:

Carla Fernandes Sudheer Giddaluru Tatiana Polushina Anne Kristin Stavrum Ghazal Zakeri

Ambitions for 2016

 Perform methylation typing in a large subset of the TOP sample to analyze the effect of environmental factors and disease on the DNA methylation.

 Initialize the characterization of the effect of Cannabis on stem cells from patients.

 Characterize the allelic heterogeneity at the region level between schizophrenia and related traits.

(17)

International Cooperation

The research requires close cooperation with leading research environments, both national and international. The researchers are participating in a series of international networks, and have several bilateral research programs with international institutions, both in the European Union and in USA. In addition to this, the Centre works actively to recruit excellent researchers internationally.

The Centre facilitates the exchange of staff between the participants and international collaborators. In 2015 we had 3 post docs abroad, and 4 international guest researchers were associated with the Centre.

International Guest Researchers

Anders M. Dale and Wes Thompson, UCSD, USA; Sven Cichon, Basel, Switzerland; Frank Larøi, Liege, Belgium.

Scientific Advisory Committee

NORMENT has established an Advisory Committee of external scientific researchers. Their tasks are as follows:

 Contribute to NORMENT’s research activity by evaluating and advising on the activities within each of the research groups of the Centre and by acting as scientific advisors to the Centre Director.

 Contribute by giving an annual lecture at postgraduate level.

 Take an active part in NORMENT’s annual Meetings.

 Participate in preparing an annual written evaluation with SWOT analysis.

 Provide advice to the NORMENT leadership in strategic decisions

Marcella Rietschel, Professor at University of Mannheim.

Terry Jernigan,

Professor at University

of California. San Diego

Michael Foster Green,

Professor at University of

California. Los Angeles.

(18)

Olav Smeland, post doc Idun Huflåtten, project

assistent

Elina Reponen, PhD.

student

Sahar Hassani, post doc Jon Alm Eriksen,

scientist Maj Egeland, PhD.

student

Andrea Raballo, post

doc Tiril Gurholt, post doc Lisa Jannicke Kjønigsen

Torgeir Moberget, post

doc Trude Jahr, PhD. student Asma Asgher, consultant

Margrethe Collier, PhD.

student

Magnus Engen, PhD.

student

Liliana Buer, research assistant

Torbjørn Elvsåshagen, post doc

Siv hege Lyngstad, PhD.

student Aldo Palomera, post doc

Antonio Pietro, bio engineer

Åshild Maria Eftevåg, administrative manager/coordinator

Christian M. Jørgensen, scientist

Priyanthi Borgen Gjerde, PhD student

New employees

(19)

NORMENT staff

Core Researchers Ingrid Agartz, Professor Ingrid Melle, Professor Kenneth Hugdahl, Professor Kjetil Sundet, Professor

Ole A. Andreassen, Professor Srdjan Djurovic, Professor Stephanie Le Hellard, Professor Vidar M. Steen, Professor Senior scientists

Erik Gunnar Jönsson, Professor Erik Johnsen, Professor II Ingrid Dieset, Associate Professor Lars Ersland, Scientist, MR-physiciste Lars Tjelta Westlye, Associate Professor Renate Grüner, Associate professor Thomas Espeseth, Associate Professor Torill Ueland, Associate Professor Trine Vik Lagerberg, Senior Scientist Unn Haukvik, Associate Professor Post docs

Akiah Ottesen Berg, PhD in psychology Aldo Palomera, PhD in biostatistics Andrea Raballo, PhD in medicine Andrew Brown, PhD in biostatistics Anja Vaskinn, PhD in psychology

Anne Kristine Stavrum, PhD in informatics Carmen Simonsen, PhD in psychology Cecilie Bhandari Hartberg, PhD in medicine Dag Alnæs, PhD in psychology

Daniel Quintana, PhD in psychology Francesco Bettella, PhD in biostatistics Ida Sønderby, PhD in molecular genetics Kari M. Ersland, PhD in biomedicine Kristina Kompus, PhD in psychology

Lavinia Athanasiu, PhD in molecular genetics Monica Aas, PhD in psychology

Nhat Trung Doan, PhD in medical imaging Olav Smeland, PhD in medicine

Raj Bose, PhD in molecular biology Sahar Hassani, PhD in biostatistics Sigrun Hope, PhD in psychology Silje Skrede, PhD in biomedicine

Sudheer Giddaluru, PhD in biostatistics Tatiana Polushina, PhD in mathematics Tiril Gurholt, PhD in neuroimaging Tobias Kaufmann, PhD in psychology Tomasz Stokowy, PhD in bioinformatics Tone Hellvin, PhD in psychology Torbjørn Elvsåshagen, PhD in medicine Torgeir Moberget, PhD.

Verena Zuber, PhD in biostatistics Yunpeng Wang, PhD in biostatistics Research Fellows/PhD students Beathe Haatveit, MSc

Camilla Büchmann, cand.psychol.

Carla Fernandes, MSc

Christine Demmo, cand.psychol Christine Lycke Brandt, MSc Elina Reponen, cand. psychol.

Elisabeth Lange, cand.med.

Erlend Gardsjord, cand.med.

Erlend S. Dørum, cand. med.

Eva Hoseth, cand.med.

Geneviève Richard, MA.psychol.

Ingeborg Bolstad, MSc

Jannicke Fjæra Anderssen, cand.psychol.

Jens Marius Halvorsen, cand.psychol.

June Lystad, cand.psychol.

Kjetil Nordbø Jørgensen, cand.psychol.

Kristina Skåtun, MSc Kristine Engen, cand.med.

Levi Kvitland, cand.psychol.

Liv Falkenberg, MSc Luiz Goulart, cand.med.

Lynn Mørk Johnsen, cand.med.

Magnus Engen, cand. psychol.

Maiken Brix, cand.med.

Maj Egeland, cand.psychol.

Margarethe Collier, cand.psychol.

Mari Nerhus, cand.med.

Marit Haram, cand.med.

Nathalia Zak, cand.med.

Niladri Banerjee, MSc

Priyanthi B. Gjerde, cand.med.

Saurabh Srinivasan, MSc Siren Tønnessen, cand.psychol.

Siv Hege Lyngstad, cand. Psychol.

Tiril Østefjells, cand.psychol.

(20)

20 | N O R M E N T A n n u a l R e p o r t 2 0 1 5 Trude Jahr, cand. psychol.

Vera Lonning, cand.med.

Other Research Personnel Christian Melbø-Jørgensen, MSc Galyna Kovalchuk, MA.psychol Ghazal Zakeri

Hanne Smevik, MA.psychol

Idun Bernadotte Huflåtten, cand psychol.

Inger Duus, research student in medicine Jon Alm Eriksen, scientist.

Kristoffer Grimstad, cand.psychol.

Liliana Buer

Lisa Jannicke Kjønigsen

Malik M. H. Taqi, PhD in molecular genetics Martina J. Lund, MA.psychol.

Natalia Tesli, MA cognitive science Nina C. Mathiesen, MA.psychol.

Tale Moldestad , cand pscyhol.

Vilja Bidtnes, cand psychol.

Technical and Administrative Positions Alex Craven, research technician

Asma Asgher, consultant Bilal Safdar, economist

Christine Stansberg, senior engineer Eivind Bakken, head nurse

Elin Inderhaug, bioengineer Gerard Dwyer, research technician Hans-Richard Brattbakk, chief engineer Jeanette Haatveit, admin. consultant Jorunn Bringsli, chief engineer

Kate Eli Frøland, senior excecutive officer Kristine Kjeldal, MSc

Lars Johan Hansson, MSc Lena Stabell, psychiatric nurse Line Gundersen, nurse

Linn Bonaventura Norbom, technical assistant Marianne Navdal, lab engineer

Ragnhild Bettina Storli, admin. consultant Rita Holdhus, chief engineer

Runar Kristiansen, database assistant Seyran Khalili, consultant

Stener Nerland, technical assistant Tanzeela Parveen, medical secretary Thomas Bjella, database consultant Vegard K. Lillevoll, IT engineer Øyvind Rustan, scientific assistant

Åshild Eftevåg, admin. manager /coordinator

(21)

Activities 2015

Visits Abroad

Agartz, I. Led the Stockholm early onset adolescent psychosis cohort (data

collection).Within the early onset psychosis study: visited Scandinavian Child Psychiatry Units. Stockholm, Sweden.

Aminoff, S.R; Andreassen O.A., Betella, F.;

LeHellard S, Lagerberg TV, Melle I, Aas M.

Meeting with collaborators in the bipolar research group at University of Paris

(professors Bruno Etain, Chantal Henry, Frank Bellevier), meeting October, Paris, France.

Andreassen OA, Visited University of California, San Diego in four periods. Research meetings and presentations. San Diego, USA.

Andreassen OA, Visited University of Southern California, July, LA, USA.

Andreassen OA, Visited EU ImageMend General Assembly, October. Mallorca Banerjee, N. Attendance at the ENCODE User’s Group Meeting & Research Applications workshop. June 29 – July 1, Maryland, USA.

Doan, N.T. Participation in “Bayesian data analysis” course at University of St. Gallen, Switzerland.

Gurholt, T. P Collaboration initiated with a researcher at Harvard University, December.

Boston, USA.

Hellard SL. Attendance at the World Congress of Psychiatric Genetics, October 16-20.

Toronto, Canada.

Hugdahl, K. International project collaboration Prof. Iris Sommer, Utrecht University Medical Center, November. Netherlands.

Hugdahl, K. International project collaboration Prof. Svyastolov Medvedev, Human Brain Institute, Russian Academy of Sciences, St Petersburg. September, Russia.

Hugdahl, K. International project collaboration, Prof. Renaud Jardri, Department of Psychiatry, University of Lille, France.

Johnsen, E. Collaboration with Prof.

Fleischhacker’s schizophrenia group, Innsbruck, Austria; Prof. Stephen Hart, Vancouver, Canada; Prof. Rene Kahn, Iris Sommer, Utrecht, the Netherlands.

Kaufmann, T. Research stay at the Child and Youth Psychiatry, University of Tübingen, Germany.

Kaufmann, T. Travel to collaboration partner at Max Planck Institute. September, Berlin, Germany.

Lagerberg, T.V. International cooperation seminar psychosis research, September.

Lucca, Italy.

Mäki-Marttunen, T. Research stay in May, San Diego, USA.

Melle, I. European College of Neuropsychopharmacology (ECNP)

Schizophrenia Research Group, April, Venice, Italy and September, Amsterdam, Netherlands.

Melle, I. European Network Research Negative Symptoms (EURONES), September Berlin, Germany.

Moberget, T. Visit to Prf. Richard Ivry, UC Berkeley, November 15 – December 15.

California, USA.

Moberget, T. Visit to Profs. Daniel Mathalon and Judith Ford at UC San Francisco December 11, San Francisco, USA.

Moberget, T. Visits to Profs. Scott Makeig, Anders Dale and Bradley Voytek, UC San Diego. December 10, San Diego, USA.

(22)

22 | N O R M E N T A n n u a l R e p o r t 2 0 1 5 Raballo, A. Research network on Basic

Symptoms (Translating Risk Symptoms for Psychosis into Neurobiological Targets).

Collaborators: Schultze-Lutter F. University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.

Simonsen, C. visits 5^th European Conference on Schizophrenia Research (ECSR).

September. Berlin, Germany.

Smeland, O.B. Research stay at Anders Dale’s lab in November 20-30. San Diego, USA.

Steen VM. Attendance at the European Society for Human Genetics 2015 congress, June 6-9. Glasgow, United Kingdom.

Ueland, T. Visit to Los Angeles for Cognitive remediation, depression meeting. LA, USA

Østefjells, T. Two researches’ stays at Dr.

Rachel Loewy, UCSF, San Francisco, USA.

Visits from Abroad

Hugdahl, K visit from prof Jardri to Bergen February. International Consortium on Hallucination Research (ICHR).

Melle, I. Lagerberg TV, Ueland T. Professor Lex Wunderink, associate professor Marieke Pijnenbord , University of Groningen.

September, Netherlands.

Steen VM. Professor Joris Veltman

(Department of Human Genetics, Radbound University Medical Center, the Netherlands) visited us in November.

Vaskinn, A. Visit from international speaker Richard Keefe.

(23)

New initiative

Patients with mental disorders have higher rates of cardiovascular disease

In recent decades there has been a marked increase in life expectancy in the general population of western countries. However, this has not been the case for patients with mental disorders. On average patients with mental disorders live 15-20 years shorter than the general population. This increase in mortality can be explained both by unnatural causes such as suicides or accidents, and natural causes, where cardiovascular disease is most important. Studies

show that patients with mental disorders are twice as likely to succumb from cardiovascular disease. Although part of this increased risk for cardiovascular disease is due to accumulation of well-known risk factors such as smoking, poor diet, diabetes, and obesity, it has been difficult to prevent and treat cardiovascular disease in this patient group. This is an important public health issue that needs to be dealt with.

NORMENT leads new initiative

Researchers at NORMENT have worked extensively on these issues in recent years. We have together with other European research groups found that part of the increased incidence for

cardiovascular disease among patients with mental disorders is connected with their genetic material and is coded in their DNA. To understand more about how gene variants can increase the incidence of cardiovascular disease, it is necessary to have a more detailed mapping of the DNA. Therefore NORMENT has initiated several national and European collaborative projects, aiming to utilize information from the establishment of a common database. The database will contain information about environmental factors and DNA gene variants that will provide new knowledge about the overlap in causal factors between mental disorders and cardiovascular disease. The plans are to include data from a large number of people from Scandinavia making it easier to extract knowledge from the database.

We will utilize the latest developments in analytical methods to map the genome of patients with mental disorders. The analysis will be performed in collaboration with researchers in Iceland, who recently have discovered genetic variants among Icelanders that increase the risk of schizophrenia, other brain disorders as well as cardiovascular disease risk factors. We will expand these findings to a European setting and test the methodology in patients from other European countries. The project will allow researchers to detect several types of gene variants which have not been possible using

previous methods. This applies both to gene variants that increase the risk of disease, and how these interact with environmental factors.

Potentially large societal benefits

The initiative could have major health benefits. By uncovering gene variants associated with cardiovascular disease and mental disorders, our understanding of these diseases and their relationship will improve. This information can lead to the development of new diagnostic tools that make it easier to determine which individuals are at increased risk for disease. It can also provide researchers with important knowledge for the development of new and better medicines with fewer side effects that are tailored specifically for different (or individual) patients. Ultimately, we hope that the project will contribute to reducing the high rate of cardiovascular disease among patients with mental disorders and improve the life prospects for this large group of people.

(24)

Selected presentations

International presentations:

Aas, M. Speaker at the symposium: "The interaction between early life stress and genetic background: shaping the brain towards psychopathology". Society of Biological

Psychiatry’s 70th Annual Scientific Congress, May 14-16, Toronto, Ontario, Canada.

Aas, M. Speaker at the symposium: "Patient perspectives, quality of life and affective symptoms in the early treated course of psychotic disorders". 5th European Conference on Schizophrenia Research (ECSR). September 24 - 26, Berlin, Germany.

Andreassen, OA. Speaker at NCP. “Shared genetic background for psychiatric disorders”

Copenhagen, Denmark.

Andreassen, OA. Speaker at USC: “New statistical approach to polygenic diseases and phenotypes” Los Angeles, USA.

Berg, A.O. Speaker at the symposium: “Clinical and socio-cultural measures of insight in immigrants in their first episode of psychosis”.

5th European conference on Schizophrenia research, Symposium “Improving

outcomes“ September 25. Berlin, Germany.

Djurovic, S. Speaker at the symposium:

“Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular disease risk factors/lipids” and chair of the session Lipid Science, Nov. 30- Dec. 2. San Francisco.

Hugdahl, K. Keynote speaker 25^th Anniv Conference Bechtereva Institute of Human Brain. September, St Petersburg, Russia.

Kaufmann, T. Speaker at the University:

“Functional brain networks”, University of Tübingen, December, Tübingen, Germany.

Lystad, J. Speaker at the symposium:

"Neurocognition and occupational functioning in Schizophrenia Spectrum Disorders " 15th

International Congress on Schizophrenia Research, Colorado Springs

Mäki-Marttunen, T. Speaker at the symposium:

“Modeling of functional schizophrenia-linked genetic variants on single-neuron properties”

Satellite workshop “Computational biophysical psychiatry: From genes to systems” of

Bernstein conference, Berlin.

Melle, I. Keynote speaker at Nordic Psychiatric Association, September. Copenhagen,

Denmark.

Melle, I. Speaker at the European

Schizophrenia Conference, September. Berlin, Germany,

Nerhus, M. Speaker at the symposium: ECSR September 24.-26, Berlin.

Raballo, A. Speaker at the symposium: “La mente prodromica: psicopatologia degli stati mentali a rischio [The prodromal mind:

psychopathology of at risk mental states” 47°

Congresso Nazionale Società Italiana di Psichiatria. October 11-15, Giardini Naxos.

Raballo, A. Speaker at the symposium: ”Moody Minds: Dysphoria and Schizophrenia Spectrum Psychopathology” Phenomenology of

Dysphoria. 23rd European Congress of Psychiatry (EPA 2015): "Excellence in

Psychiatry across Europe: Practice, Education, Research”, March 28-31, Wien, Austria.

Simonsen, C. Speaker at the symposium:

“Early clinical recovery in first episode

psychosis: correlates of symptomatic remission at 1 year follow-up” 5^th European conference on Schizophrenia Research (ECSR).

September 24. Berlin.

Vaskinn, A. Speaker at the symposium:

“Gender differences in neuropsychological performance in psychosis” the first European Meeting of Women’s Mental Health in Barcelona, Spain

(25)

25 | N O R M E N T A n n u a l R e p o r t 2 0 1 5 Witoelar, A. Speaker at the symposium:

”Extracting the last bits of information from GWAS summary statistics” for Computer science colloquium, University of Groningen, Netherlands

National dissemination:

Aas, M. Speaker: "Barndomstraumer og psykose” Tidlig Psykose Symposium, juni 2.

Bergen, Norway.

Agartz, I. Speaker: “NMDA NR2 and cognition in autoimmune diseases” Academic opposition, Stavanger University Hospital. Stavanger, Norway

Banerjee, N. Speaker: “Investigating the implication of human specific methylated regions in complex disorders” Bioinformatics in Bergen (BiB) meeting. September 7-9. Sotra, Norway

Berg, A.O. Speaker: "Migrasjon og

symptomprofiler ved psykoselidelser" Norsk forskningsråd PSYKISK HELSE OG

RUSMIDDELFORSKNING, Ubehag i kulturen eller kultur i ubehaget. 2. februar Oslo, Norway.

Bettella, F. Speaker: ”Genetic Markers of Human Evolution are Enriched in

Schizophrenia ”Forskerkonferanse om psykisk helse og rus. Oslo, Norway.

Hellard, SL. Speaker: “Genetics of Schizophrenia and a pinch of epigenetics”

Bioinformatics in Bergen (BiB) meeting.

September 7-9, Sotra, Norway.

Johnsen, E. Speaker: ” Antipsychotics and the influence on somatic health” Bergen tidlig psykosesymposium; Antipsykotika og

betydning for somatisk helse, NFRs forskningskonferanse for psykisk helse og rusmiddelforskning. Tromsø, Norway.

Lagerberg, T.V. Speaker: ”Hva er det med rus og bipolar lidelse – og hva kan vi forebygge”

Forelesning åpen temakveld om bipolar lidelse.

Oslo, Norway.

Lystad, J. Speaker: "Kognisjon, kognitive vansker og kognitiv trening". Fagkonferansen - Attføringsbedriftene, Kristiansand, Norway.

Lystad, J. Speaker: "Kognitive vansker og kognitiv trening", TIPS Konferansen, september. Oslo, Norway

Nerhus, M. Speaker: ”Blir vi glade av lys?

Årstider og vitamin D ved psykiske lidelser” Det Norske Vitenskaps Akademi -

jubileumsseminar om lys. 11.november Oslo, Norway.

Polushina, T. Speaker: “Multiple testing problem in biostatistics” The 18th Norwegian statistical meeting.June 15-18. Solstrand, Norway.

Quintana, D. Speaker: Heart rate variability seminar - Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Simonsen, C. Speaker: ”Sykdomsforløp og bedring ved psykoselidelser: miljøets betydning.” Plenary lecture at conference:

Psykologikongressen. Oslo kongresssenter – September 4. Oslo, Norway.

Stokowy, T. Speaker: “Detection of causative variants of rare monogenic phenotypes in whole genome sequencing data”.

Bioinformatics in Bergen (BiB) meeting.

September 7-9, Sotra, Norway

Ueland, T. Speaker: ” Kognitiv funksjon og arbeid i Jobbmestrende oppfølging: resultater over tre måletidspunkt med fokus på kognitiv trening” NAV, Drammen, Norway

(26)

26 | N O R M E N T A n n u a l R e p o r t 2 0 1 5 Josef Bless

15.10.2015

«The smartphone as a research tool in psychology.

Assessment of language lateralization and training of auditory attention»

Supervisor: Kenneth Hugdahl

Nasrettin Sønmez 29.05.2015

«Depressive symptoms and cognitive behavior therapy in first episode psychosis»

Supervisor: Jan Ivar Røssberg

Elen Gjevik 27.05.2015

«Psychiatric comorbidity in children with autism spectrum disorder – from genes to clinical characteristics.»

Supervisor: Ole Andreas Andreassen

Carla P.D. Fernandes 05.03.2015

«A genetic study of schizophrenia and bipolar disorder – A cognitive endophenotype approach»

Supervisor: Stephanie Le Hellard

Disputations

(27)

NORMENT in the Media

 Aas M. Media: ”Jakter på hjernens gåter” http://forskning.no/blogg/akademiet-yngre-forskere/pa- jakt-etter-hjernens-uloste-gater-mot-monica-aas Forskning.no

 Andreassen OA. interview: Gene variants for brain size discovered: “Researchers have

discovered several new gene variants that influence brain volume. We are yet another step closer to finding the causes of a number of psychological disorders”

http://www.med.uio.no/klinmed/english/research/news-and-events/news/2015/gene-variants-brain- size.html

 Berg, A.O. and Nerhus, M. Media: http://forskning.no/vitaminer-psykiske-lidelser/2015/03/tran-og- d-vitamin-enda-sunnere-enn-du-tror. April 07, Forskning.no

 Berg, A.O. Media: “Om traumer, dissosiasjon og psykose i et transkulturelt perspektiv”

http://rop.no/artikler/tenk-fellesskap-i-behandling-av-traumer August 18. ROP-TV

 Berg, A.O. Media: ”Differensialdiagnostikk ved traumelidelser” https://youtu.be/JH-JkL7LhMs

 Berg, A.O. Media: ”Ingen pårørende” http://www.psykologforeningen.no/publikum/blogger/fip- blogg/ingen-paaroerende November 19, Blogg Norsk Psykologforening

 Hugdahl, K: "De 100 mest produktive forskerne". Nettavis "På Høyden" [Internett] 2015-02-16 UiB

 Hugdahl, K: Banebrytende hjerneforskning ved UiB. Katarsis - et tidsskrift for studenter ved det psykologiske fakultet 2015 UiB

 Johnsen, E: Letters to the editor, Klassekampen March 2015; NRK Hordaland http://www.nrk.no/hordaland/elektriske-stot-skal-fjerne-stemmene-1.12703888

 Johnsen, E: Litteraturhuset I Bergen http://www.litthusbergen.no/program/2015/03/schizofreni- psyk-for-alltid/; Tvangsforsk Holmen fjorhotell; pårørendeseminar, pårørendeundervisning engruppe.

 Kaufmann, T. http://www.med.uio.no/norment/forskning/aktuelt/aktuelle-saker/2015/fremragende- forskningsartikler-.html

 Mäki-Marttunen, T. “Neuronal modelling for schizophrenia research”, an article for “NOTUR Meta”

magazine.

 Quintana, D.: “Mye oksytocin – mindre angst”  - Journal of the Norwegian Medical Association 01/11/15 http://tidsskriftet.no/article/3413518/

 Quintana, D.: “Nesespray kan hjelpe psykisk syke” - Forskning.no 13/08/15 http://forskning.no/2015/08/nesespray-mot-psykiske-lidelser

 Quintana, D: “Could A Hormone Nasal Spray Help People With Mental Illness And Autism?” – Forbes Magazine 31/08/15 http://www.forbes.com/sites/emilymullin/2015/08/31/could-a-hormone- nasal-spray-help-people-with-mental-illness-and-autism/#4b84301c1d22

 Smeland, O.B. Media: “Hvorfor har mennesker med psykiske lidelser økt forekomst av hjerte- karsykdom?” http://www.med.uio.no/norment/forskning/aktuelt/aktuelle-saker/2015/hjerte- karsykdom-og-psykisk-lidelse.html

 Srinivasan, S. and Bettella F. “Schizofreni er et biprodukt av hjernens utvikling”

http://forskning.no/helse-psykiske-lidelser/2016/02/schizofreni-er-et-biprodukt-av-hjernens- utvikling

 Le Hellard S. Article: “Utfordringer og fremskritt ved genetisk forskning på schizofreni”. Best Practice Psykiatri/Nevrologi. Desember 2015

 Steen VM and Hellard SL. Commentary article: «Hjernestrukturers størrelse har sammenheng med DNA-variasjon». The Journal of the Norwegian Medical Association», nr. 10, 2015.

 Vaskinn, A.: http://www.abcnyheter.no/nyheter/2015/04/08/221620/ni-prosent-av-amerikanere-har- vapentilgang-og-impulsivt-sinne

(28)

Publications

Books:

1. Aminoff, S.R., Berg, O.A., Lagerberg, T.V., Melle, I., Simonsen, C., Ueland, T., Aas, M. Samfunn and psykose. Universitetsforlaget

2. OA Andreassen, M Tesli. Imaging genetics of bipolar disorder. Neuroimaging Genetics: Principles and Practices, Oxford University Press, 2015 Articles:

1. Agcaoglu O, Miller R, Mayer AR, Hugdahl K, Calhoun VD. Increased spatial granularity of left brain activation and unique age/gender signatures: a 4D frequency domain approach to cerebral lateralization at rest. Brain Imaging Behav. 2015 Oct 21.

2. Agcaoglu O, Miller R, Mayer AR, Hugdahl K, Calhoun VD. Lateralization of resting state networks and relationship to age and gender. Neuroimage. 2015 Jan 1;104:310-25

3. Gjevik E, Sandstad B, Andreassen OA, Myhre AM, Sponheim E. Exploring the agreement between questionnaire information and DSM-IV diagnoses of comorbid psychopathology in children with autism spectrum disorders. Autism. 2015 May;19(4):433-42.

4. Alnæs D, Kaufmann T, Richard G, Duff EP, Sneve MH, Endestad T, Nordvik JE, Andreassen OA, Smith SM, Westlye LT. Attentional load modulates large- scale functional brain connectivity beyond the core attention networks. Neuroimage. 2015 Apr 1 5. Alnæs D, Sneve MH, Richard G, Skåtun KC,

Kaufmann T, Nordvik JE, Andreassen OA, Endestad T, Laeng B, Westlye LT. Functional connectivity indicates differential roles for the intraparietal sulcus and the superior parietal lobule in multiple object tracking. Neuroimage. 2015 Dec;123:129-37.

6. Aminoff SR, Tesli M, Bettella F, Aas M, Lagerberg TV, Djurovic S, Andreassen OA, Melle I. Polygenic risk scores in bipolar disorder subgroups. J Affect Disord.

2015 Sep

7. Andreassen OA, Desikan RS, Wang Y, Thompson WK, Schork AJ, Zuber V, Doncheva NT, Ellinghaus E, Albrecht M, Mattingsdal M, Franke A, Lie BA, Mills IG, Aukrust P, McEvoy LK, Djurovic S, Karlsen TH, Dale AM. Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One. 2015 Apr 8;10(4):e0123057.

8. Andreassen OA, et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol Psychiatry. 2015 Feb

9. Andreou D, Söderman E, Axelsson T, Sedvall GC, Terenius L, Agartz I, Jönsson EG. Cerebrospinal fluid monoamine metabolite concentrations as

intermediate phenotypes between glutamate-related genes and psychosis. Psychiatry Res. 2015 Sep 30 10. Arnfred SM, Raballo A, Morup M, Parnas J. Self-

disorder and brain processing of proprioception in schizophrenia spectrum patients: a re-analysis.

Psychopathology. 2015

11. Athanasiu L, Smorr LL, Tesli M, Røssberg JI, Sønderby IE, Spigset O, Djurovic S, Andreassen OA.

Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs. J Psychopharmacol. 2015 Aug;29(8):884-91.

12. Barder HE, Sundet K, Rund BR, Evensen J, Haahr U, ten Velden Hegelstad W, Joa I, Johannessen JO, Langeveld J, Larsen TK, Melle I, Opjordsmoen S, Røssberg JI, Simonsen E, Vaglum P, McGlashan T, Friis SP. 10 year course of IQ in first-episode psychosis: relationship between duration of psychosis and long-term intellectual trajectories. Psychiatry Res.

2015 Feb 28;225(3):515-21.

13. Barrett EA, Mork E, Færden A, Nesvåg R, Agartz I, Andreassen OA, Melle I. The development of insight and its relationship with suicidality over one year follow-up in patients with first episode psychosis.

Schizophr Res. 2015 Mar;162(1-3):97-102.

14. Bauer M, Glenn T, Alda M, Andreassen OA et al.

Influence of light exposure during early life on the age of onset of bipolar disorder. J Psychiatr Res. 2015 May;64:1-8.

15. Bauer M, Glenn T, Alda M, Andreassen OA, et al.

Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. Eur Psychiatry. 2015 16. Berg AO, Aas M, Larsson S, Nerhus M, Hauff E,

Andreassen OA, Melle I. Childhood trauma mediates the association between ethnic minority status and more severe hallucinations in psychotic disorder.

Psychol Med. 2015 Jan;45(1):133-42.

17. Berg AO, Barrett EA, Nerhus M, Büchman C, Simonsen C, Faerden A, Andreassen OA, Melle I.

Psychosis: clinical insight and beliefs in immigrants in their first episode. Early Interv Psychiatry. 2015 Dec 18. Bless JJ, Westerhausen R, von Koss Torkildsen J,

Gudmundsen M, Kompus K, Hugdahl K. Laterality across languages: Results from a global dichotic listening study using a smartphone application.

Laterality. 2015;20(4):434-52.

19. Bolstad I, Andreassen OA, Groote IR, Haatveit B, Server A, Jensen J. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol. Front Hum Neurosci. 2015 May 26;9:296.

20. Brandt CL, Doan NT, Tønnesen S, Agartz I, Hugdahl K, Melle I, Andreassen OA, Westlye LT. Assessing brain structural associations with working-memory related brain patterns in schizophrenia and healthy controls using linked independent component analysis.

Neuroimage Clin. 2015 Aug 21;9:253-63.

21. Brandt CL, Kaufmann T, Agartz I, Hugdahl K, Jensen J, Ueland T, Haatveit B, Skatun KC, Doan NT, Melle I, Andreassen OA, Westlye LT. Cognitive Effort and Schizophrenia Modulate Large-Scale Functional Brain Connectivity. Schizophr Bull. 2015 Nov;41(6):1360-9.

doi: 10.1093/schbul/sbv013.

22. Bratlien U, Øie M, Haug E, Møller P, Andreassen OA, Lien L, Melle I. Self-reported symptoms and health service use in adolescence in persons who later

(29)

develop psychotic disorders: a prospective case- control study. Early Interv Psychiatry. 2015 Jun 23. Brix MK, Ersland L, Hugdahl K, Grüner R, Posserud

MB, Hammar Å, Craven AR, Noeske R, Evans CJ, Walker HB, Midtvedt T, Beyer MK. "Brain MR spectroscopy in autism spectrum disorder-the GABA excitatory/inhibitory imbalance theory revisited". Front Hum Neurosci. 2015 Jun 22;9:365.

24. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Patterson N, Daly MJ, Pricem AL, Neale BM. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015 Mar;47(3):291

25. Chen CH … Westlye LT, Kremen WS, Jernigan TL, Le Hellard S, Steen VM, Espeseth T, Huentelman M, Håberg AK, Agartz I, Djurovic S, Andreassen OA, Schork N, Dale AM; Pediatric Imaging Neurocognition and Genetics Study; Alzheimer's Disease

Neuroimaging Initiative. Large-scale genomics unveil polygenic architecture of human cortical surface area.

Nat Commun. 2015 Jul 20;6:7549.

26. Clark KA, Helland T, Specht K, Narr KL, Manis FR, Toga AW, Hugdahl K. Reply: Cortical differences in preliterate children at familiar risk of dyslexia are similar to those observed in dyslexic readers. Brain.

2015 Sep;138(Pt

27. Dahl J, Andreassen OA, Verkerk R, Malt UF, Sandvik L, Brundin L, Ormstad H. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.

Psychoneuroendocrinology. 2015 Jun;

28. Davies G, … Eriksson JG, Espeseth T, et al. Genetic contributions to variation in general cognitive function:

a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53949). Mol Psychiatry. 2015 Feb;20(2):183-92.

29. Desikan R … Andreassen OA, Dale AM; Inflammation Working Group and International Genomics of Alzheimer’s Disease Project (IGAP) and DemGene Investigators. Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease.

Circulation. 2015 Jun 9;131(23):2061-9.

30. Desikan RS … Andreassen OA, Dale AM et al.; ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators.

Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry. 2015 Dec;20(12):1588-95.

31. Dieset I, Haukvik UK, Melle I, Røssberg JI, Ueland T, Hope S, Dale AM, Djurovic S, Aukrust P, Agartz I, Andreassen OA. Association between altered brain morphology and elevated peripheral endothelial markers--implications for psychotic disorders.

Schizophr Res. 2015 Feb;161(2-3):222-8.

32. Dybedal GS, Tanum L, Sundet K, Bjølseth TM. The Role of Baseline Cognitive Function in the

Neurocognitive Effects of Electroconvulsive Therapy in Depressed Elderly Patients. Clin Neuropsychol.

2015;29(4):487-508.

33. Elvsåshagen T, Moberget T, Bøen E, Hol PK, Malt UF, Andersson S, Westlye LT. The surface area of early visual cortex predicts the amplitude of the visual evoked potential. Brain Struct Funct. 2015 Mar;22

34. Elvsåshagen T, Norbom LB, Pedersen PØ, Quraishi SH, Bjørnerud A, Malt UF, Groote IR, Westlye LT.

Widespread changes in white matter microstructure after a day of waking and sleep deprivation. PLoS One. 2015 May 28;10(5):e0127351.

35. Ersland KM, Skrede S, Røst TH, Berge RK, Steen VM.

Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine. J Psychopharmacol.

2015 Dec;29(12)

36. Fernø J, Ersland KM, Duus IH, González-García I, Fossan KO, Berge RK, Steen VM, Skrede S.

Olanzapine depot exposure in male rats: Dose- dependent lipogenic effects without concomitant weight gain. Eur Neuropsychopharmacol. 2015 Jun;25

37. Fjell AM, Westlye LT, Amlien I, Tamnes CK, Grydeland H, Engvig A, Espeseth T, Reinvang I, Lundervold AJ, Lundervold A, Walhovd KB. High- expanding cortical regions in human development and evolution are related to higher intellectual abilities.

Cereb Cortex. 2015 Jan;25(1):26-34.

38. Frech TM, Revelo MP, Ryan JJ, Shah AA, Gordon J, Domsic R, Hant F, Assassi S, Shanmugam VK, Hinchcliff M, Steen V, Khanna D, Bernstein EJ, Cox J, Luem N, Drakos S. Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. J Med Case Rep. 2015 Jun 10;9:136.

39. Fretland RA, Andersson S, Sundet K, Andreassen OA, Melle I, Vaskinn A. Theory of mind in schizophrenia:

error types and associations with symptoms.

Schizophr Res. 2015 Mar;162(1-3):42-6.

40. Friis S, Melle I, et al. TH. Early Predictors of Ten-Year Course in First-Episode Psychosis. Psychiatr Serv.

2015 Nov 16

41. Gjevik E, Sandstad B, Andreassen OA, Myhre AM, Sponheim E. Exploring the

42. Goulart LF, Bettella F, Sønderby IE, Schork AJ, Thompson WK, Mattingsdal M,Steen VM, Zuber V, Wang Y, Dale AM; PRACTICAL/ELLIPSE consortium, Andreassen OA, Djurovic S. MicroRNAs enrichment in GWAS of complex human phenotypes. BMC Genomics. 2015 Apr 16;16:304.

43. Grellmann C, Bitzer S, Neumann J, Westlye LT, Andreassen OA, Villringer A, Horstmann A.

Comparison of variants of canonical correlation analysis and partial least squares for combined analysis of MRI and genetic data. Neuroimage. 2015 Feb 15

44. Grindstad, T, Andersen, S, Al-Saad,S,; Dønnem, T, Kiselev, Y., Melbø-Jørgensen, C., Skjefstad, K., Busund, L, Bremnes, R., Richardsen, E.

High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS ONE 2015. -UiT UNN

45. Grydeland H, Westlye LT, Walhovd KB, Fjell AM.

Intracortical Posterior Cingulate Myelin Content Relates to Error Processing: Results from T1- and T2- Weighted MRI Myelin Mapping and Electrophysiology in Healthy Adults. Cereb Cortex. 2015 Apr 2.

46. Gupta CN … Andreassen O, Agartz I et al. Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysis. Schizophr Bull.

2015 Sep;41(5):1133-42